Thurston Springer Miller Herd & Titak Inc. Purchases 1,862 Shares of Eli Lilly and Company $LLY

Thurston Springer Miller Herd & Titak Inc. increased its position in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 10.8% during the second quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 19,071 shares of the company's stock after buying an additional 1,862 shares during the quarter. Eli Lilly and Company comprises about 1.9% of Thurston Springer Miller Herd & Titak Inc.'s portfolio, making the stock its 6th biggest position. Thurston Springer Miller Herd & Titak Inc.'s holdings in Eli Lilly and Company were worth $14,868,000 at the end of the most recent reporting period.Get Eli Lilly and Company alerts:Vanguard’s VUG ETF: The Ultimate Growth ETF for Your PortfolioOther institutional investors have also added to or reduced their stakes in the company. WestEnd Advisors LLC raised its stake in Eli Lilly and Company by 210.0% during the 1st quarter. WestEnd Advisors LLC now owns 31 shares of the company's stock worth $26,000 after buying an additional 21 shares during the period. Wealth Preservation Advisors LLC acquired a new position in Eli Lilly and Company during the 1st quarter worth approximately $27,000. Citizens National Bank Trust Department raised its stake in Eli Lilly and Company by 180.0% during the 1st quarter. Citizens National Bank Trust Department now owns 42 shares of the company's stock worth $35,000 after buying an additional 27 shares during the period. Financial Gravity Asset Management Inc. acquired a new position in Eli Lilly and Company during the 1st quarter worth approximately $40,000. Finally, Mascagni Wealth Management Inc. acquired a new position in Eli Lilly and Company during the 4th quarter worth approximately $43,000. 82.53% of the stock is owned by institutional investors and hedge funds. Wall Street Analyst Weigh InSeveral brokerages have recently commented on LLY. Deutsche Bank Aktiengesellschaft lowered their price objective on Eli Lilly and Company from $1,010.00 to $900.00 and set a "buy" rating for the company in a research note on Monday, August 11th. Daiwa America downgraded Eli Lilly and Company from a "strong-buy" rating to a "hold" rating in a research note on Sunday, August 17th. Cantor Fitzgerald lowered their price objective on Eli Lilly and Company from $975.00 to $825.00 and set an "overweight" rating for the company in a research note on Wednesday, August 13th. Morgan Stanley reissued an "overweight" rating and issued a $1,135.00 price objective (up from $1,133.00) on shares of Eli Lilly and Company in a research note on Thursday, July 10th. Finally, UBS Group lowered their price objective on Eli Lilly and Company from $1,050.00 to $895.00 and set a "buy" rating for the company in a research note on Friday, August 8th. One research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and eight have assigned a Hold rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $941.35.As the Market Rotates, This Healthcare ETF Is Leading the WayCheck Out Our Latest Report on Eli Lilly and CompanyInsider Buying and SellingIn related news, Director J Erik Fyrwald purchased 1,565 shares of Eli Lilly and Company stock in a transaction dated Tuesday, August 12th. The stock was bought at an average cost of $642.33 per share, for a total transaction of $1,005,246.45. Following the completion of the transaction, the director owned 74,578 shares in the company, valued at $47,903,686.74. This trade represents a 2.14% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO David A. Ricks purchased 1,632 shares of Eli Lilly and Company stock in a transaction dated Tuesday, August 12th. The stock was bought at an average price of $644.77 per share, with a total value of $1,052,264.64. Following the completion of the transaction, the chief executive officer owned 546,601 shares of the company's stock, valued at $352,431,926.77. This represents a 0.30% increase in their position. The disclosure for this purchase can be found here. Insiders bought 4,514 shares of company stock valued at $2,894,841 in the last 90 days. Corporate insiders own 0.13% of the company's stock. Eli Lilly and Company Price PerformanceOzempic Boom: Hims & Eli Lilly Lead Healthcare BetsShares of NYSE LLY opened at $754.90 on Friday. The stock has a fifty day simple moving average of $741.03 and a two-hundred day simple moving average of $776.40. Eli Lilly and Company has a 1-year low of $623.78 and a 1-year high of $942.35. The firm has a market cap of $714.48 billion, a price-to-earnings ratio of 49.34, a price-to-earnings-growth ratio of 1.05 and a beta of 0.47. The company has a current ratio of 1.28, a quick ratio of 1.00 and a debt-to-equity ratio of 1.86. Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The company reported $6.31 earnings per share for the quarter, beating the consensus estimate of $5.59 by $0.72. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The business had revenue of $15.56 billion during the quarter, compared to analyst estimates of $14.40 billion. During the same period in the prior year, the company earned $3.92 earnings per share. Eli Lilly and Company's revenue was up 37.6% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. Analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current year. Eli Lilly and Company Dividend AnnouncementThe business also recently declared a quarterly dividend, which was paid on Wednesday, September 10th. Stockholders of record on Friday, August 15th were given a $1.50 dividend. The ex-dividend date was Friday, August 15th. This represents a $6.00 annualized dividend and a dividend yield of 0.8%. Eli Lilly and Company's payout ratio is 39.22%. Eli Lilly and Company Company Profile (Free Report)Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.See AlsoFive stocks we like better than Eli Lilly and CompanyWhy Invest in High-Yield Dividend Stocks?Ride the Luxury Retail Wave with These 3 High-End Brand StocksElection Stocks: How Elections Affect the Stock MarketWall Street Quietly Bets Big on These Chinese Tech GiantsRussell 2000 Index, How Investors Use it For Profitable TradingMeta's $600B U.S. Investment: Bearish or Bullish for Shares? This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.Should You Invest $1,000 in Eli Lilly and Company Right Now?Before you consider Eli Lilly and Company, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list.While Eli Lilly and Company currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here